

Tentative Outline
Special Issue for Current Drug Metabolism
Guest Editor: Jose A.G. Agúndez

**CLINICAL USE OF BIOMARKERS IN DRUG METABOLISM
AND ADVERSE DRUG REACTIONS**

Aims & Scope:

In spite of the large effort and the huge amount of pharmacogenomics information available in the literature, until now only a small number of pharmacogenomics biomarkers are being used routinely in clinical practice. Several barriers to implementing the use of pharmacogenomics testing exist. This special issue will focus on developments, barriers and regulatory issues regarding clinical use of biomarkers. These will include (but not limited to) new procedures for the identification of biomarkers (NG sequencing, microRNAs, exploitation of the 1000 genomes project); Barriers to implementing the use of pharmacogenomics testing; Non-genetic biomarkers of drug response; Identification and validation of Gene/drug pairs; Refinement in the predictive capacity of conventional pharmacogenomic tests; Development of clinical practice recommendations or guidelines for the clinical use of biomarkers related to drug response.

Keywords:

Biomarkers, pharmacogenetics, drug response, gene/drug pairs, barriers, refinement, bioinformatics, guidelines.

Subtopics:

Barriers in the clinical use of biomarkers.
Pharmacogenomic tests: gene-drug pairs.
Refinement of the predictive capacity of biomarkers.
New challenges in the use of pharmacogenomic biomarkers.
New computational approaches for the exploitation of genetic data.

Schedule:

Manuscript submission deadline: July 2013

Peer Review Due: August 2013

Revision Due: September 2013

Notification of acceptance by the Guest Editor: October 2013

Final manuscripts due: October 2013